Serum prolidase I activity and some bone metabolic markers in patients with breast cancer: In relation to menopausal status

Clinical Biochemistry

Volumn 36, Issue 4, 2003, Pages 289-294

  Kir, Zeynep Özbek ^a   Öner, Pernur ^a   Iyidoǧan, Yildiz Öner ^a   Türkmen, Sembol ^b   Koçak, Hikmet ^a   Koşer, Murat ^a   Küçücük, Seden Özbilen ^c  

^a ISTANBUL UNIVERSITY   (Turkey)

^b OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^c ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bone involvement; Bone metastases; Bone turnover markers; Breast cancer; Menopausal status; Serum prolidase I

Indexed keywords

BIOCHEMICAL MARKER; BIOLOGICAL MARKER; CALCIUM; DEOXYPYRIDINOLINE; ISOPROTEIN; OSTEOCALCIN; PROLINE DIPEPTIDASE;

ADULT; ARTICLE; BONE METABOLISM; BONE TURNOVER; BREAST CARCINOMA; CALCIUM EXCRETION; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; METASTASIS; OSTEOBLAST; OSTEOCLAST; PRIORITY JOURNAL; SERUM; STATISTICAL SIGNIFICANCE; URINALYSIS;

EID: 0038517977     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9120(03)00028-6     Document Type: Article

References (27)

1. Haskell CM, Casciato DA. Breast Cancer. In: Manual of Oncology, Lowitz B (ed) Little Brown, USA, 1995; 3. Ed Chap. 10. 183-99.
2. Fimiani M., Rubegni P., de Aloe G., Bilenchi R., Andreassi L. Squamous cell carcinoma of the leg in a patient with prolidase deficiency. Br J Dermatol. 140:1999;362-363.
3. Delmas P.D. Biochemical markers of bone turnover. Acta Orthop Scand. 66:1995;176-182.
4. Myara I., Myara A., Mangeot M., Fabre M., Charpentier C., Lemonnier A. Plasma prolidase activity a possible index of collagen catabolism in chronic liver disease . Clin Chem. 30:1984;211-215.
5. Karna E., Surazynski A., Palka J. Collagen metabolism disturbances are accompanied by an increase in prolidase activity in lung carcinoma planoepitheliale. Int J Exp Pathol. 1:2000;341.
6. Wolanska M., Sobolewski K., Drozdzewicz M. Integrins and prolidase activity in uterine leiomyoma during tumor growth. Ginekol Pol. 72:2001;121-126.
7. Wolczynski S., Surazynski A., Swiatecka J., Palka J. Estrogenic and antiestogenic effects of raloxifene on collagen metabolism in breast cancer MCF-7 cells. Gynecol Endocrinol. 15:2001;225-233.
8. Cosson C., Myara I., Miech G., Moatti N., Lemonnier A. Only prolidase I activity is present in human plasma. Int J Biochem. 24:1992;427-432.
9. Brosset B., Myara I., Fabre M., Lemonnier A. Plasma prolidase and prolinase activity in alcoholic liver disease. Clin Chim Acta. 175:1988;291-296.
10. Foucre D., Bouchet C., Hacene K., Pourreau-Schneider N., Gentile A., Martin P.M., Desplaces A., Oglobine J. Relationship between cathepsin D, urokinase and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer. 64:1991;926-932.
11. Koizumi M., Yamada Y., Takiguchi T. Bone metabolic markers in bone metastases. J Cancer Res Clin Oncol. 121:1995;542-548.
12. Miura H., Yamamoto I., Takada M., Kigami Y., Ohta T., Yuu I., Hamanaka Y., Matsushita R., Morita R. Diagnostic validity of bone metabolic markers for bone metastasis. Endocrine J. 44:1997;751-757.
13. Paterson C.R., Robins S.P., Horobin J.M., Preece P.E., Cuschieri A. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer. 64:1991;884-886.
14. Blomqvist C., Risteli L., Risteli J., Virkkunen P., Sarna S., Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer. 73:1996;1074-1079.
15. Berruti A., Torta M., Piovesan A., Raucci C.A., Orlandi F., Panero A., Dogliotti L., Angeli A. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res. 5:1995;2871-2876.
16. Martinetti A., Bajetta E., Seregni E., Zilembo N., Ferrari L., Noberasco C., Massaron S., Rimassa L., Bombardieri E. Serum markers of bone metastases in postmenopausal breast cancer patients treated with formestane. Tumor Biol. 18:1997;197-205.
17. Endres D.B., Rude R.K. Mineral and bone metabolism. Burtis C.A., Ashwood E.R. Tietz Textbook of Clinical Chemistry. 1994;1887-1973 Saunders Co, Philadelphia, USA. 2 ed Chap 36.
18. Norusis T. SPSS PC+4 Base Manual. 1990;SPSS Inc, Chicago, Illinois.
19. Miltyk W., Anchim T., Wolczynski S., Palka J. Estrogen-dependent regulation of prolidase activity in breast cancer MCF-7 cells. Gynecol Endocrinol. 13:1999;166-174.
20. Orr F.W., Kostenuik P., Sanchez-Sweatman O.H., Singh G. Mechanism involved in the metastasis of cancer to bone. Breast Cancer Res Treat. 25:1993;151-163.
21. Body J.J., Cleeren A., Pot M., Borkowski A. Serum osteocalcin (BGP) in tumor-associated hypercalcemia. J Bone Min Res. 1:1986;523-527.
22. Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW, Ryo UY. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: comparison with serum PSA/PAP measurements. J Nucl Med.1990; 1486-9.
23. Maeda H., Koizumi M., Yoshimura K., Yamauchi T., Kawai T., Ogata E. Correlation between bone metabolic markers and bone scan in prostatic cancer. J Urol. 157:1997;539-543.
24. Ikeda I., Miura T., Kondo I. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. Br J Urol. 77:1996;102-106.
25. Westerhuis L.W.J.J.M., Delaere K.P.J. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer. Eur J Clin Chem Clin Biochem. 35:1997;89-94.
26. Lipton A., Demers L., Daniloff Y., Curley E., Hamilton C., Harvey H., Witters L., Seaman J., Van der Giessen R., Seyedin S. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem. 39:1993;614-618.
27. Takeuchi S., Arai K., Saitoh H., Yoshida K., Miura M. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 156:1996;1691-1695.